-+ 0.00%
-+ 0.00%
-+ 0.00%

Lake Street Maintains Buy on Kyntra Bio, Lowers Price Target to $8

Benzinga·11/17/2026 19:12:05
Diffusion vocale
Lake Street analyst Daniel Brims maintains Kyntra Bio (NASDAQ:KYNB) with a Buy and lowers the price target from $41 to $8.